Search Videos and More
Video
2026 ASCO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates
Video
2026 ASCO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates
Video
2026 ASCO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.
Video
ASCO26: Toni Choueiri, MD, KEYNOTE-654
Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.
Video
2026 AACR Renal Cell Carcinoma Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.
Video
2026 AACR Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.
Video
2026 AACR Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.
News
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.
News
Dana-Farber’s Dr. Toni Choueiri Elected to the Association of American Physicians
Dana-Farber Cancer Institute’s Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology, was recently elected to one of the nation’s most prestigious medical organizations, The Association of American Physicians (AAP).
News
Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer
The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant immunotherapy.
News
Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025
Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.
News
Chain Reaction: The Belzutifan Journey
Countless medical innovations are born in academic laboratories.